Key Drivers
- Strong Margins
- Solid Cash Flow
- High Leverage
AIAI Summary
Smith+Nephew now looks less like a turnaround and more like an execution test: despite solid cash generation, margins, and a $500m buyback, the stock will likely stay capped unless management converts product momentum in sports medicine and wound care into sustained revenue growth and margin leverage, because the market is still treating rallies as selling opportunities.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Solid Cash Flow
- •High Leverage
SNN looks financially solid with strong margins and cash flow, but leverage, intangible-heavy assets, and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support holding
- •Resistance overhead
Over the last month, SNN is down about 14% and remains in a fragile downtrend below $31.00–$31.30 resistance, though repeated holds above $29.10–$29.50 suggest near-term support may be forming.
Decline slowed near $29.10, with a brief rebound back above $30.00
Sentiment & News
Key News Insights:
- •Revenue momentum
- •Share buyback
- •Product adoption
Smith & Nephew posted solid Q1 revenue growth, kept full-year guidance unchanged, and reinforced its outlook with a $500 million buyback plus encouraging product and wound-care pipeline updates.
The latest updates suggest stable near-term performance with improving product traction and shareholder returns, supporting a constructive outlook for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings